Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
World Journal of Urology
|
October 6, 2006
Treatment options for BCG failures
Michael A O'Donnell, Andreas Boehle
Journal of Cancer Research and Clinical Oncology
|
January 28, 2021
Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial)
Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, et al.
Urologic Oncology
|
September 15, 2023
LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients
Andreas Boehle, Dorothea Zywietz, Irina Robrahn-Nitschke, et al.
Advances in Radiation Oncology
|
February 27, 2023
Definitions of "Cure" After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
Andreas Boehle, Dorothea Zywietz, Irina Robrahn-Nitschke, et al.
Brachytherapy
|
October 21, 2019
Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy
Andreas Boehle, Katharina Katic, Inke R König, et al.
European Urology
|
January 29, 2011
European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update
Morgan Rouprêt, Richard Zigeuner, Juan Palou, et al.
Clinical Chemistry
|
July 28, 2004
Ki-67 protein concentrations in urothelial bladder carcinomas are related to Ki-67-specific RNA concentrations in urine
Tim B Menke, Katrin Boettcher, Stefan Krüger, et al.
European Urology
|
July 5, 2005
EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ
Adrian P M van der Meijden, Richard Sylvester, Willem Oosterlinck, et al.
Nature Reviews. Urology
|
March 2, 2017
BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG
Ashish M Kamat, Marc Colombel, Debasish Sundi, et al.
BJU International
|
January 18, 2020
Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)
Justin T Matulay, Mark Soloway, J Alfred Witjes, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
World Journal of Urology
|
October 6, 2006
Treatment options for BCG failures
Michael A O'Donnell, Andreas Boehle
Journal of Cancer Research and Clinical Oncology
|
January 28, 2021
Re: Results of a randomized trial of treatment modalities in patients with low or early‑intermediate risk prostate cancer (PREFERE trial)
Andreas Boehle, Frank Kahmann, Thomas Oliver Henkel, et al.
Urologic Oncology
|
September 15, 2023
LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients
Andreas Boehle, Dorothea Zywietz, Irina Robrahn-Nitschke, et al.
Advances in Radiation Oncology
|
February 27, 2023
Definitions of "Cure" After Low-Dose-Rate Brachytherapy in Low- and Intermediate-Risk Prostate Cancer: Phoenix or Surgical?
Andreas Boehle, Dorothea Zywietz, Irina Robrahn-Nitschke, et al.
Brachytherapy
|
October 21, 2019
Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy
Andreas Boehle, Katharina Katic, Inke R König, et al.
European Urology
|
January 29, 2011
European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update
Morgan Rouprêt, Richard Zigeuner, Juan Palou, et al.
Clinical Chemistry
|
July 28, 2004
Ki-67 protein concentrations in urothelial bladder carcinomas are related to Ki-67-specific RNA concentrations in urine
Tim B Menke, Katrin Boettcher, Stefan Krüger, et al.
European Urology
|
July 5, 2005
EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ
Adrian P M van der Meijden, Richard Sylvester, Willem Oosterlinck, et al.
Nature Reviews. Urology
|
March 2, 2017
BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG
Ashish M Kamat, Marc Colombel, Debasish Sundi, et al.
BJU International
|
January 18, 2020
Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG)
Justin T Matulay, Mark Soloway, J Alfred Witjes, et al.
Page
of 2